Association between genetic variants in glutathione peroxidase 1 gene and risk of prostate cancer: a meta-analysis.

To examine the association between glutathione peroxidase 1 (GPx1) gene Pro198Leu polymorphism with the development and progression of prostate cancer. A comprehensive search was conducted to identify all case-control studies of GPx1 polymorphisms and prostate cancer. Statistical analysis was performed with the software program Stata, version 11.0, and Review Manage, version 4.2. A total of 7 eligible studies relating the GPx1 polymorphism to the risk of prostate cancer were identified. The results indicated no significant association between GPx1 polymorphisms and prostate cancer susceptibility in the dominant model (random effects OR 0.75, 95 % CI 0.48-1.18), recessive model (random effects OR 0.47, 95 % CI 0.22-1.01) and co-dominant genetic model (random effects OR 0.72, 95 % CI 0.43-1.21). For the analysis of GPx1 polymorphism and progression of prostate cancer, no significant association were found in the dominant model (fixed effects OR 1.20, 95 % CI 0.95-1.52), recessive model (fixed effects OR 0.69, 95 % CI 0.48-1.00) and co-dominant genetic model (fixed effects OR 0.95, 95 % CI 0.79-1.15). Egger's test showed that publication bias was not present in all the comparisons.

Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis.

OBJECTIVES: To examine the association between fibroblast growth factor receptor-4 (FGFR-4) genetic polymorphisms (Gly-388Arg) and prostate cancer susceptibility. METHODS: A comprehensive search was conducted to identify all case-control studies of FGFR-4 polymorphisms and prostate cancer risk. Statistical analysis was performed with the software program Stata, version 8.0, and Review Manage, version 4.2. RESULTS: A total of 4 eligible studies, including 2,618 cases and 2,305 controls, relating the FGFR-4 polymorphism to the risk of prostate cancer were identified. The overall results indicated a significant association between FGFR-4 polymorphisms and prostate cancer. In the subgroup analysis by ethnicity, a significant association was found between European descent for recessive model (random effects OR 0.82, 95% CI 0.72-0.93) and co-dominant genetic model (random effects OR 0.83, 95% CI 0.68-1.00). Sensitivity analysis also found a significant association in the recessive (random effects OR 0.68, 95% CI 0.49-0.95) or the co-dominant (random effects OR 0.68, 95% CI 0.49-0.96) models. Egger's test showed that publication bias was not present in any of the comparisons. CONCLUSIONS: Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent.

Characterizing the critical features when personalizing antihypertensive drugs using spectrum analysis and machine learning methods.

Globally, methods of controlling blood pressure in hypertension patients remain inefficient. The difficulty of prescribing appropriate drugs specific to a patient's clinical features serves as one of the most important factors. Characterizing the critical drug-related features, just like that of the antibacterial spectrum (where each item is sensitive to the targeted drug's effectiveness or a specified indication), may help a doctor easily prescribe appropriate drugs by matching a patient's attributes with drug-related features, and effectiveness of the selected drugs would also be ascertained. In this study, we aimed to apply data mining methods to obtain the clinical characteristics spectrum or important clinical features of five frequently used drugs (Irbesartan, Metoprolol, Felodipine, Amlodipine, and Levamlodipine) for hypertension control by comparing successful and unsuccessful cases. Spectrum analysis based on a statistical method and five algorithms based on machine learning were used to extract the critical clinical features. A visualized relative weight matrix was then achieved by combining the results from the characteristic spectrum and machine learning-based methods. Our results indicated that the five targeted antihypertension agents had different importance orders of the 15 relative clinical features. Clinical analysis showed that the extracted important clinical attributes of the five drugs were both reasonable and meaningful in the selection of hypertension treatment. Therefore, our study provided a data-driven reference for the personalization of clinical antihypertensive drugs.

Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis.

OBJECTIVES: To examine the association between 2 mitochondrial manganese superoxide dismutase (MnSOD) genetic polymorphisms (Ala-9Val and Ala-16Val) and prostate cancer susceptibility. METHODS: A comprehensive search was conducted to identify all case-control studies of MnSOD polymorphisms and prostate cancer risk. Statistical analysis was performed with the software program Stata, version 8.0, and Review Manage, version 4.2. RESULTS: A total of 9 eligible studies, including 3268 cases and 5907 controls, relating the MnSOD polymorphism to the risk of prostate cancer were identified. For the Ala-9Val polymorphism, 5 studies, including 889 cases and 1841 controls, found no significant associations between MnSOD polymorphism and the risk of developing prostate cancer in the recessive, dominant, and co-dominant models. In the sensitivity analysis, exclusion of the study with the controls not in Hardy-Weinberg equilibrium, no significant associations were also found in the recessive (odds ratio [OR] 1.29, 95% confidence interval [CI] 0.66-2.50), dominant (OR 1.35, 95% CI 0.84-2.17), and co-dominant (OR 1.33, 95% CI 0.87-2.01) models. For the Ala-16Val polymorphism, 4 studies, including 2379 cases and 4066 controls, found no significant association between MnSOD polymorphism and the risk of developing prostate cancer in both co-dominant (OR 1.08, 95% CI 1.00-1.16), recessive (OR 1.06, 95% CI 0.94-1.20) and dominant (OR 1.14, 95% CI 1.00-1.28) models. CONCLUSIONS: No significant association was found between the Ala-9Val and Ala-16Val polymorphisms in MnSOD and prostate cancer susceptibility.